GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
Lockheed Martin Secures $1.14 Billion Contract Boost for F-35 Production 
Pentagon Probe Finds Hegseth’s Use of Signal Risked Exposing Sensitive Yemen Strike Details 
Honduras Awaits Final Election Results as Asfura Holds Slim Lead Amid U.S. Attention 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
Australia Progresses AUKUS Review as U.S. Affirms Strong Support 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
Trump’s New U.S. Strategy Seeks to Deter China and Protect Taiwan 
CFPB to Review Anti-Discrimination Policies and Fair Lending Rules Amid Policy Shift 
China’s Expanding Maritime Military Presence Alarms Taiwan and Japan 
Honduras Election Turmoil Intensifies as Nasralla Blames Trump for Shift in Results 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
Taiwan Opposition Criticizes Plan to Block Chinese App Rednote Over Security Concerns 
IKEA Expands U.S. Manufacturing Amid Rising Tariffs and Supply Chain Strategy Shift 
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
Cantor Fitzgerald analysts are calling for the dismissal of U.S. Health and Human Services Secretary Robert F. Kennedy Jr., citing his controversial anti-vaccine views and lack of scientific expertise. In a note released Monday, Cantor’s Josh Schimmer and Eric Schmidt warned that Kennedy is “undermining the trusted leadership of health care in this country.”
Kennedy recently announced plans to restructure federal health agencies, potentially firing thousands of staff. The move comes on the heels of the resignation of Peter Marks, the FDA’s top vaccine official, who reportedly left under pressure from the administration. Marks had been known for his data-driven approach to vaccine safety and his resistance to what Cantor described as an “anti-science agenda.”
Biotech and vaccine stocks dropped following Marks’ resignation, with the SPDR S&P Biotech ETF (NYSE:XBI) falling 3.9%. Despite the market reaction, Cantor analysts stressed their concerns were about public health, not politics or stock performance.
Cantor Fitzgerald, a major Wall Street firm previously led by Howard Lutnick—now Commerce Secretary under Trump—has recently passed leadership to his sons. Brandon Lutnick now serves as chairman, while Kyle Lutnick holds the position of executive vice chairman.
The analysts expressed hope that Washington leadership will recognize the critical role of vaccines in safeguarding public health. They emphasized the need for scientifically grounded leadership at the Department of Health and Human Services, warning that Kennedy’s conspiracy-driven stance could endanger lives.
Cantor Fitzgerald has yet to comment publicly on the matter.
This development marks a significant flashpoint in the Trump administration’s overhaul of federal health agencies, stirring concern among biotech investors and public health experts alike.
